Gyre Therapeutics (GYRE) Equity Average: 2009-2025
Historic Equity Average for Gyre Therapeutics (GYRE) over the last 17 years, with Sep 2025 value amounting to $133.4 million.
- Gyre Therapeutics' Equity Average rose 39.12% to $133.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $133.4 million, marking a year-over-year increase of 39.12%. This contributed to the annual value of $41.3 million for FY2024, which is 46.44% up from last year.
- As of Q3 2025, Gyre Therapeutics' Equity Average stood at $133.4 million, which was up 14.17% from $116.9 million recorded in Q2 2025.
- In the past 5 years, Gyre Therapeutics' Equity Average registered a high of $133.4 million during Q3 2025, and its lowest value of -$27.1 million during Q2 2023.
- Moreover, its 3-year median value for Equity Average was $91.1 million (2024), whereas its average is $59.2 million.
- Its Equity Average has fluctuated over the past 5 years, first slumped by 151.12% in 2023, then surged by 1,699.19% in 2024.
- Gyre Therapeutics' Equity Average (Quarterly) stood at $50.9 million in 2021, then fell by 0.23% to $50.8 million in 2022, then plummeted by 112.12% to -$6.2 million in 2023, then surged by 1,699.19% to $98.4 million in 2024, then surged by 39.12% to $133.4 million in 2025.
- Its Equity Average stands at $133.4 million for Q3 2025, versus $116.9 million for Q2 2025 and $101.4 million for Q1 2025.